Evidence map›Paper›PMID 25652703›Full record

ArticleJournal of biomedical optics2015

Tomography of epidermal growth factor receptor binding to fluorescent Affibody in vivo studied with magnetic resonance guided fluorescence recovery in varying orthotopic glioma sizes.

Robert W Holt, Jennifer-Lynn H Demers, Kristian J Sexton, Jason R Gunn, Scott C Davis, Kimberley S Samkoe, Brian W Pogue

Open access · hybridAbstract read
In one paragraph

Article in Journal of biomedical optics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Estimating drug delivery using hybrid system for simultaneous dynamic MRI and fluorescence tomography.Proceedings of SPIE--the International Society for Optical Engineering · 2020
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Robert W HoltDartmouth College, Department of Physics & Astronomy, Hanover, New Hampshire 03755, United States.
Jennifer-Lynn H DemersDartmouth College, Thayer School of Engineering, Hanover, New Hampshire 03755, United States.
Kristian J SextonDartmouth College, Thayer School of Engineering, Hanover, New Hampshire 03755, United States.
Jason R GunnDartmouth College, Thayer School of Engineering, Hanover, New Hampshire 03755, United States.
Scott C DavisDartmouth College, Thayer School of Engineering, Hanover, New Hampshire 03755, United States.
Kimberley S SamkoeDartmouth College, Thayer School of Engineering, Hanover, New Hampshire 03755, United StatescGeisel School of Medicine at Dartmouth, Department of Surgery, Hanover, New Hampshire 03755, United States.
Brian W PogueDartmouth College, Department of Physics & Astronomy, Hanover, New Hampshire 03755, United StatesbDartmouth College, Thayer School of Engineering, Hanover, New Hampshire 03755, United StatescGeisel School of Medicine at Dartmouth, Department of Surgery, H.
Dartmouth College · US

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
Small Molecule Enhancers of Photodynamic Therapy for Skin CancerP01CA084203 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Bryan Quilty Spring · 2001 to 2026
$27.9M
Molecular Fluorescence-Guided Surgery PlatformR01CA167413 · NCI · DARTMOUTH COLLEGE · PI PAULSEN, KEITH D., SAMKOE, KIMBERLEY · 2013 to 2025
$5.7M
Fluorescence Imaging to Optimize Cancer TherapyR01CA109558 · NCI · DARTMOUTH COLLEGE · PI POGUE, BRIAN WILLIAM · 2005 to 2015
$2.8M
MRI fluorescence tomography for quantifying tumor receptor concentration in vivoR01CA184354 · NCI · DARTMOUTH COLLEGE · PI DAVIS, SCOTT C · 2014 to 2018
$2.6M
NCI NIH HHS P01 CA084203NCI NIH HHS P30 CA023108NCI NIH HHS R01 CA109558NCI NIH HHS R01 CA167413NCI NIH HHS R01 CA184354
6 · The paper itself

Abstract

The ability to image targeted tracer binding to epidermal growth factor receptor (EGFR) was studied in vivo in orthotopically grown glioma tumors of different sizes. The binding potential was quantified using a dual-tracer approach, which employs a fluorescently labeled peptide targeted to EGFR and a reference tracer with similar pharmacokinetic properties but no specific binding, to estimate the relative bound fraction from kinetic compartment modeling. The recovered values of binding potential did not vary significantly as a function of tumor size (1 to 33 mm3), suggesting that binding potential may be consistent in the U251 tumors regardless of size or stage after implantation. However, the fluorescence yield of the targeted fluorescent tracers in the tumor was affected significantly by tumor size, suggesting that dual-tracer imaging helps account for variations in absolute uptake, which plague single-tracer imaging techniques. Ex vivo analysis showed relatively high spatial heterogeneity in each tumor that cannot be resolved by tomographic techniques. Nonetheless, the dual-tracer tomographic technique is a powerful tool for longitudinal bulk estimation of receptor binding.

Indexed as

AnimalsBrain ChemistryBrain NeoplasmsCell Line, TumorErbB ReceptorsFluorescent DyesGliomaHeadHumansImage Processing, Computer-AssistedMagnetic Resonance ImagingMiceMice, NudeProtein BindingRecombinant Fusion ProteinsTomography, OpticalErbB ReceptorsFluorescent DyesRecombinant Fusion Proteins

Identifiers

PMID25652703
PMCPMC4317247
OpenAlexW1991321370

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.